Trials / Terminated
TerminatedNCT03676231
Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SGM-1019 Administered for 12 Weeks in Subjects With F1-F3 Nonalcoholic Steatohepatitis (NASH)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Second Genome · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, pharmacokinetics, and pharmacodynamics of 12 weeks' administration of SGM-1019 in subjects with fibrosis stage 1-3 (F1-F3) NASH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGM-1019 | Active |
| DRUG | Placebo | Inactive |
Timeline
- Start date
- 2019-01-18
- Primary completion
- 2019-05-01
- Completion
- 2019-05-01
- First posted
- 2018-09-18
- Last updated
- 2019-07-11
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03676231. Inclusion in this directory is not an endorsement.